Latham & Watkins Advises Mirador Therapeutics in US$400 Million Venture Financing

Mirador Therapeutics, Inc. (Mirador) has announced its launch. Founded by Mark C. McKenna and led by several former executives of Prometheus Biosciences (acquired in 2023 by Merck for US$10.8 billion), Mirador aims to revolutionize precision medicine for immune-mediated inflammatory and fibrotic diseases by leveraging its proprietary Mirador360TM development engine to rapidly advance multiple programs. Mirador has raised more than US$400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other premier life sciences investors also participated, including Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners LP, Venrock Healthcare Capital Partners, RTW Investments and Alexandria Venture Investments.

Latham & Watkins LLP advised Mirador Therapeutics in the financing with a corporate team led by San Diego partners Matt Bush and Cheston Larson, with associate Alex Stuart-Lovell.